Clinical Trial Update: Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause [Phase 3]

View source ↗

Summary

Phase 3 study evaluating DVS-233 SR for vasomotor symptoms associated with menopause has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hot Flashes
• Menopause
• Sleep Disorders

Drugs mentioned

• DVS-233 SR

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Menopause, Hot Flashes | Phase 3 | Status: COMPLETED